CRD-B vs GHY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CRD-B exhibits significant valuation disconnects, trading at $9.94 despite a Graham Number of $5.58 and an Intrinsic Value of $2.73. While the Piotroski F-Score of 4/9 indicates stable health, this is offset by deteriorating fundamentals, including a -11.20% YoY revenue decline and a -21.1% YoY EPS drop. The technical trend is completely bearish (0/100), and the company has missed 3 of its last 4 earnings estimates. Despite a low forward P/E, the lack of actual growth makes the current premium unjustifiable.
GHY exhibits severe fundamental weakness, highlighted by a critical Piotroski F-Score of 1/9, indicating poor financial health. The fund is currently trading at $11.91, a significant premium over its growth-based intrinsic value of $8.75. While the dividend yield is high at 10.58%, the payout ratio of 100.80% suggests the distribution is unsustainable and potentially eroding capital. Combined with a 0/100 technical trend and bearish insider sentiment, the risk-reward profile is unfavorable.
Compare Another Pair
Related Comparisons
CRD-B vs GHY: Head-to-Head Comparison
This page compares Crawford & Company (CRD-B) and PGIM Global High Yield Fund, Inc (GHY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.